Previously dba FibrosiX LLC, and renamed FibroIX Inc, the firm is a start-up anchored in technology licensed from University of Michigan and Michigan State University. Focused on the needs of patients with scleroderma (and other fibrotic diseases) - scleroderma being chronic connective tissue disease classified as one of the autoimmune rheumatic diseases - currently treated with anti- inflammatory drugs and immunosuppressants known to have major side effects while also not address an underlying cause. Despite years of research, no effective drugs are available to treat those underlying causes. With the licenced technology related to compounds that inhibit the MRTF/SRF gene transcription mechanism - MRTF pathway inhibitors - FibrosIX is addressing the development of novel anti-fibrotic agents that disrupt gene transcription. Addressing the problem from a totally different direction with the technology licensed - small molecule anti-fibrotic therapeutics to prevent the progression of fibrotic diseases - work is now underway at FibrosIX offers the promise of better outcomes.
